Table 2B:

Clinicopathological metrics and PDO drug screening results for patients treated with gemcitabine/abraxane (GnP) in NAT setting.

PDO ID	Timing of Tissue Collection for PDOa	Chemotherapy Tumor Before Surgical Resection (doses)	NAT Radiation (doses)	CA 19–9 Percent Decrease (%)b	Radiographic Tumor Size Percent Decrease (%)c	Surgical Pathology Tumor Cellularity (%)d	Pathology NAT Responsee	RFS (months)f	Biobank Predicted Response	PDO Sensitivity/Resistance AUC
hT294	post-NAT	GnP (4)		86	40	92	3		Gem = A Pac = A	Gem: 0.69 Pac: 0.62 AUC sum:1.30
hT220	post-NAT	GnP (3)		78	6	83	3	3.7	Gem = R Pac = S	Gem: 0.79 Pac:0.56 AUC sum : 1.35
hF161	pre-NAT			78	6	83	3	3.7	Gem = R Pac = S	Gem: 0.84 Pac:0.55 AUC sum : 1.39
hT241	post-NAT	mFFX(6)-> GnP (6)	3000cGy	88	8	75	2	7.8 mon	Gem= S Pac = S	Gem:0.50 Pac:0.56 AUC sum: 1.06
hT213	post-NAT	GnP (3)		85	20	36	2	11.1 mon	Gem = R Pac = R	Gem:0.75 Pac:0.67 AUC sum: 1.42

Abbreviations: PDO, patient-derived organoids; GnP, gemcitabine/abraxane; mFFX, modified FOFIRINOX; NAT, neoadjuvant; RFS, recurrence free survival; R, resistant; S, sensitive; A, average.

^aPre-NAT, biopsy specimen obtained prior to initiation of NAT chemotherapy; post-NAT, surgical specimen obtained after NAT completion at the time of primary tumor resection.

^bThe change in CA 19–9 levels before and after chemotherapy divided by the starting value and multiplied by 100.

^cThe change in the tumor size determined by computed tomography (CT) pancreas protocol before and after chemotherapy divided by the starting value and multiplied by 100.

^dSurgical Pathology Tumor Cellularity (%) score was calculated as the number of histology slides with viable adenocarcinoma divided by the total number of slides sampled from the resected tumor.

^eAccording CAP protocol³

^fRecurrence Free Survival (RFS) was calculated from the date of surgery until the date of recurrence.